+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention



Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention



Reviews in Cardiovascular Medicine 2(Suppl. 1): S19



Acute worsening of renal function due to contrast agents occurs in 15% to 40% of patients with baseline renal insufficiency undergoing percutaneous coronary intervention. Radiocontrast nephropathy is associated with increased morbidity, prolonged hospitalization, and higher in-hospital mortality. Our nonrandomized data suggest that in adequately hydrated patients, the dopamine-1 receptor agonist fenoldopam is a useful adjunct during PCI for prevention of RCN, reducing its incidence to less than 5%. This renoprotective effect of fenoldopam was more pronounced in diabetics, with moderate renal failure, in whom no agent has been shown so far to be beneficial.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046619001

Download citation: RISBibTeXText

PMID: 12439364


Related references

A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheterization and Cardiovascular Interventions 55(2): 169-173, 2002

Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Reviews in Cardiovascular Medicine 2(Suppl. 1): S26, 2001

Preliminary experience with fenoldopam, a new renal vasodilator, in reducing radio contrast nephropathy during percutaneous coronary intervention. American Journal of Cardiology 86(Suppl 8A): 1i, 2000

Validation of a predictive risk score for radiocontrast-induced nephropathy following percutaneous coronary intervention. Journal of Invasive Cardiology 19(5): 229-233, 2007

Radiocontrast nephropathy: managing the high-risk patient. Introduction. Reviews in Cardiovascular Medicine 2(Suppl. 1): S1-S3, 2003

Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheterization and Cardiovascular Interventions 53(3): 341-345, 2001

Prevention of contrast-induced nephropathy with haemofiltration in high-risk patients after percutaneous coronary intervention. Acute Cardiac Care 13(3): 164-169, 2011

Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention. International Urology and Nephrology 46(4): 781-786, 2014

Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Reviews in Cardiovascular Medicine 2(Suppl. 1): S4, 2001

Parathyroid hormone pth secretion increases following infusion of dopamine d but not fenoldopam f a selective dopamine 1 da1 receptor agonist in man. Clinical Research 35(6): 860A, 1987

Selective dopamine-1 receptor agonist augments regional myocardial blood flow: comparison of fenoldopam and dopamine. American Heart Journal 124(2): 418-423, 1992

Effects of dopamine and skf 82526 fenoldopam a selective dopamine 1 receptor agonist on vascular resistances in the canine fore limb. Journal of Pharmacology and Experimental Therapeutics 229(3): 756-762, 1984

Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures. Expert Opinion on PharmacoTherapy 4(5): 639-652, 2003

Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy. Journal of Clinical Pharmacology 44(12): 1342-1351, 2004

Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. American Journal of Cardiology 89(8): 999-1002, 2002